

DUOX2, a new player on the scene of thyroid hormones

Florentina RUS-HRINCU¹, MD, PhD student, Assoc. Prof. Alexandra TOTAN¹, MD, PhD, Assist. Prof. Ana Maria Alexandra STĂNESCU⁴, MD, PhD, Anca-Ioana BELUSICA², MD, Prof. Maria GREABU¹, MD, PhD

¹Department of Biochemistry, Faculty of Dental Medicine, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania

²CMI Belușică Anca, Bucharest, Romania

³Department of Family Medicine, „Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

ABSTRACT

Introduction. Thyroid disorders have very high frequency both in Romania and around the world. Nowadays new parameters are needed to diagnose thyroid disease. Clinicians need new parameters, with rapid determination, low cost, high affinity and specificity.

The aim of our study was to investigate possible relationships between thyroid hormones (TH), TSH and DUOX2, and thus a possible involvement of oxidative stress (OS) in thyroid malfunction.

Material and methods. The study included 66 patients (men and women), divided on 2 lots: 33 patients with hypothyroidism and 33 patients with hyperthyroidism. The control group was represented by 33 healthy volunteers. All the participants, patients and controls, provided the informed consent to participate in the study. The parameters analyzed were serum TSH, FT4, FT3 and DUOX2.

Results. Our results showed that in hypothyroidism patients we have lower levels of TH, and higher level of DUOX2. This suggest an accumulation of enzyme, unused for synthesis. In the meantime, in hyperthyroidism group we can observe a lower level of serum DUOX2, due to massive synthesis of TH.

Conclusions. We can assume that DUOX2 has a crucial role in TH and, by producing hydrogen peroxide, an important role in OS. Additional studies are still needed in order to establish whether DUOX2 should be regarded as useful OS biomarker in thyroid pathology.

Keywords: thyroid, thyroid hormones, dual oxidase, oxidative stress

INTRODUCTION

Thyroid disorders have very high frequency both in Romania and around the world. Nowadays new parameters are needed to diagnose thyroid disease. Parameters that highlight the exact place where the normal synthesis circuit is interrupted. This is necessary for the development of new targeted treatments that act on the affected structure and thus ensure a higher success rate. Clinicians need new parameters, with rapid determination, low cost, high affinity and specificity. The thyroid follicle is the functional structure responsible for

thyroid hormone (TH) biosynthesis, thyroxine(T4) and triiodothyronine (T3) (1,2).

Equilibria, biological variation, homeostatic interrelations and set points between thyroid stimulating hormone (TSH), FT4, and FT3 become relevant for the observed expression of multivariate normality and stability in thyroid health (1). All three routine thyroid parameters (THS, FT4, FT3) must be viewed together in order to create an appropriate image of the possible thyroidal affection (3).

A number of chemical reactions are fundamental for TH synthesis, and one of these reactions is the oxidation of the substrate in the presence of

Corresponding author:

Assoc. Prof. Alexandra Totan, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania
E-mail: alexandratotan99@gmail.com

hydrogen peroxide and a peroxidase enzyme that catalyzes the process, thyroperoxidase (TPO). The hydrogen peroxide necessary for TH biosynthesis is generated at the apical surface of the thyrocyte through a controlled reaction catalyzed by 2 members of the NADPH oxidases family, dual oxidase 1 (DUOX1) and dual oxidase 2 (DUOX2) (4-6).

The aim of our study was to investigate possible relationships between TH, TSH and DUOX2, and thus a possible involvement of oxidative stress (OS) in thyroid malfunction (7).

MATERIAL AND METHODS

The study included 66 patients (men and women), divided on 2 lots: 33 patients with hypothyroidism and 33 patients with hyperthyroidism. The control group was represented by 33 healthy volunteers. All the participants, patients and controls, provided the informed consent to participate in the study.

The parameters analyzed were serum TSH, FT4, FT3 and DUOX2. Measurement of serum TSH, FT4 and FT3 was performed using an automatic immunoassay system (IMMULITE 1000, Siemens Germany). Measurement of serum DUOX2 was performed using ELISA technique and assay kit from Abbexa UK.

TABLE 1. Experimental data obtained in control group and hypothyroidism group

Parameter	Control group	Hypothyroidism group	p
TSH (μUI/ml)	1.80±0.62	23.81±5.1	0.01
FT3 (pg/ml)	2.32±0.35	2.86±0.8	0.01
FT4 (ng/dl)	1.30±0.23	1.20±0.16	0.01
DUOX2 (ng/ml)	2.98±0.87	7.33±3	0.01

TABLE 2. Experimental data obtained in control group and hyperthyroidism group

Parameter	Control group	Hyperthyroidism group	p
TSH (μUI/ml)	1.80±0.62	0.04±0.02	0.01
FT3 (pg/ml)	2.32±0.35	4.14±1.03	0.01
FT4 (ng/dl)	1.30±0.23	2.47±0.9	0.01
DUOX2 (ng/ml)	2.98±0.87	2.65±0.7	0.01




FIGURE 1. Experimental data obtained in control group versus hypothyroidism group




FIGURE 2. Experimental data obtained in control group versus hyperthyroidism group

Statistical analysis comparison between the two studied groups was done with Student’s t test for parametric parameters.

RESULTS

Our experimental data is highlighted in Table 1 and Table 2 and represented in Figures 1 and 2. Our results showed that the patients with high levels of TSH 23.81 ±5.1 μUI/ml have increased levels of DUOX2 7.33± 3 ng/ml, compared with the levels in control group: TSH 1.80±0.62 μUI/ml and DUOX2 2.98±0.87 ng/ml; r²=0.1.

Patients with very low levels of TSH 0.04 ±0.02 μUI/ml have lower levels of DUOX2 2.65± 0.7ng/ml, compared to the levels in control group TSH 1.80±0.62 μUI/ml and DUOX2 2.98±0.87 ng/ml; r²=0.06.

DISCUSSIONS

Our results showed that in hypothyroidism patients we have lower levels of TH, and higher level of DUOX2. This suggest an accumulation of enzyme, unused for synthesis. In the meantime, in hyperthyroidism group we can observe a lower level of serum DUOX2, due to massive synthesis of TH.

We can assume that DUOX2 has a crucial role in TH and, by producing hydrogen peroxide, an important role in OS. It is known that DUOX are essential for TPO catalyzed hormone synthesis (7,8). Previous studies demonstrated that hydrogen peroxide generated by DUOX, inhibit TPO activity due to oxidative damage to the enzyme. If DUOX activity is increased, and the TPO activity is reduced, thyroid tissue could be harmed because hydrogen peroxide is less consumed by the TPO system and produced in higher amounts by DUOX. Reactive oxygen species (ROS) accumulate, leading to oxi-

ductive damage of the thyroid gland (8-11). Other studies associated OS with both hyperthyroidism and hypothyroidism however, the mechanisms are different: low availability of antioxidants in hypothyroidism and increased ROS production in hyperthyroidism. It is demonstrated in many studies the involvement of OS in numerous pathologies, and thyroid disorders are among them (12,13). Some hyperthyroidism complications in target tissues are caused by OS (14,15).

CONCLUSIONS

In conclusion we can confirm the importance of DUOX2 in thyroid dysfunction, based on the significant correlation between levels of TSH and DUOX2 ($r^2=0.1$ for hypothyroidism lot; $r^2=0.06$ for hyperthyroidism lot), and thus the involvement of OS in thyroid malfunction.

Additional studies are still needed in order to establish whether DUOX2 should be regarded as useful OS biomarker in thyroid pathology.

REFERENCES

1. Hoermann R, Midgley JEM, Larisch R et al. Relational stability in the expression of normality, variation, and control of thyroid function. *Front in endocrinol(Lausanne)* 2016; 7:142.
2. Gereben B, Zavacki AM, Ribich S et al. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. *Endocr Rev* 2008; 29 (7): 898-938.
3. Hoermann R, Midgley JEM, Giacobino A et al. Homeostatic equilibria between free thyroid hormones and pituitary thyrotropin are modulated by various influences including age, body mass index and treatment. *Clin Endocrinol* 2014;81(6): 907-915.
4. Bargi-Souza P, Goulart-Silva F, Nunes MT. Novel aspects of T3 actions on GH and TSH synthesis and secretion: physiological implications. *J Mol Endocrinol* 2017; 59(4): R167-R178.
5. Citterio CE, Veluswamy B, Morgan SJ et al. De novo triiodothyronine formation from thyrocytes activated by thyroid-stimulating hormone. *J Biol Chem* 2017; 292(37): 15434-15444.
6. Carvalho DP, Dupuy C. Role of the NADPH oxidases DUOX and NOX4 in thyroid oxidative stress. *Eur Thyroid J* 2013; 2(3): 160-167.
7. Szanto I, Pusztaszeri M, Mavromati M. H₂O₂ metabolism in normal thyroid cells and in thyroid tumorigenesis: Focus on NADPH oxidases. *Antioxidants (Basel)* 2019; 8(5):126.
8. Ohye H, Sugawara M. Dual oxidase, hydrogen peroxide and thyroid diseases. *Exp Biol Med* 2010; 235(4): 424-33.
9. Song Y, Ruf J, Lothaire P et al. Association of duoxes with thyroid peroxidase and its regulation in thyrocytes. *J Clin Endocrinol Metab* 2010; 95(1): 375-82.
10. Fortunato RS, Lima de Souza EC, Ameziame-el Hassani R et al. Functional consequences of dual oxidase-thyroperoxidase interaction at the plasma membrane. *J Clin Endocrinol Metab* 2010; 95(12): 5403-11.
11. Song Y, Driessens N, Costa M et al. Roles of hydrogen peroxide in thyroid physiology and disease. *J Clin Endocrinol Metab* 2007; 92(10): 3764-73.
12. Zheng X, Ma SG, Guo ML et al. Compound heterozygous mutations in the DUOX2/DUOXA2 genes cause congenital hypothyroidism. *Yonsei Med J* 2017; 58(4):888-890.
13. Peters C, Nicholas AK, Schoenmakers E, Lyons G, Langham S, Serra EG, Sebire NJ, Muzza M, Fugazzola L, Schoenmakers N. DUOX2/DUOXA2 mutations frequently cause congenital hypothyroidism which evades detection on UK newborn screening. *Thyroid* 2019;29(6): 790-801.
14. Ginabreda MG, Cardoso LC, Nobrega FM et al. Negative correlation between thyroperoxidase and dual oxidase H2O2-generating activities in thyroid nodular lesions. *Eur J Endocrinol* 2008;158(2): 223-7.
15. Resch U, Hesel G, Tatzber F et al. Antioxidant status in thyroid dysfunction. *Clin Chem Lab Med* 2002; 40(11): 1132-4.